Trial Profile

Real-world Data on Gi(l)Otrif Dose Adjustment in First-line Treatment, TKI-naive, Advanced Non-small Cell Lung Cancer Patients With EGFR Activating Mutations

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms RealGiDo
Sponsors Boehringer Ingelheim

Most Recent Events

26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
06 Nov 2017 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com